Fenwick represented Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, in its underwritten public offering of 3.5 million shares of its common stock at a price to the public of $70 per share, with expected gross proceeds of approximately $245 million.
Morphic also granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by Morphic.
Jefferies, Cowen, BMO Capital Markets and RBC Capital Markets acted as joint bookrunners for the offering.
More information can be obtained from Morphic’s announcement.
The Fenwick transaction team included corporate partners Robert Freedman, Effie Toshav and Julia Forbess, and associates Alice Lin, Emily Yi and Alexej Ladonnikov.